Details About Generic Salt ::  Octreoti

Main Medicine Class:: Hormone   

(ock-TREE-oh-tide ASS-uh-TATE)

Sandostatin

Sandostatin LAR Depot

Class: Hormone

Drugs Class ::

 Action Actions mimic those of natural hormone somatostatin. Suppresses secretion of serotonin and gastroenteropancreatic peptides (eg, gastrin, insulin, glucagon, secretin, motilin). Also suppresses growth hormone.

Indications for Drugs ::

 Indications Symptomatic treatment of diarrhea associated with carcinoid tumors; treatment of profuse watery diarrhea associated with vasoactive intestinal peptide tumors (VIPoma); to reduce blood levels of growth hormone and IGF-1 in acromegaly patients who have had inadequate response to or cannot be treated with resection, pituitary irradiation and bromocriptine at maximally tolerated doses. Unlabeled use(s): To reduce output from GI fistulas; for variceal bleeding; for relief of diarrhea associated with a variety of conditions; to reduce output from pancreatic fistulas; to treat irritable bowel syndrome; to treat dumping syndrome; to treat the following conditions: Enteric fistula; pancreatitis; pancreatic surgery; glucagonoma; insulinoma; gastrinoma (Zollinger-Ellison syndrome); intestinal obstruction; local radiotherapy; chronic pain management; antineoplastic therapy; decrease insulin requirements in diabetes mellitus; thryotropin- and TSH-secreting tumors.

Drug Dose ::

 Route/Dosage

Carcinoid Tumors

ADULTS: SC 100 to 600 mcg/day in 2 to 4 divided doses, adjusting to response.

VIPoma

ADULTS: SC 200 to 300 mcg/day in 2 to 4 divided doses, adjusting to response.

Acromegaly

ADULTS: SC 50 mcg to 500 mcg/tid. Most common dose is 100 mcg/tid; doses > 300 mcg/day seldom result in additional benefit.

Contraindication ::

 Contraindications Standard considerations.

Drug Precautions ::

 Precautions

Pregnancy: Category B. Lactation: Undetermined. Children: Has been used in children as young as 1 mo. Elderly: Dose adjustments may be necessary due to significant increases in half-life and significant decrease in the clearance of octreotide. Cardiac effects: In acromegalics, bradycardia, conduction abnormalities and arrhythmias have occurred. Other ECG changes observed include QT prolongation, axis shifts, early repolarization, low voltage, R/S transition and early wave progression. Dose adjustments in drugs such as beta blockers that have bradycardia effects may be necessary. Pancreatitis: Several cases have occurred in patients receiving octreotide. Cholelithiasis: Cholelithiasis may occur; periodically monitor gallbladder function. Hypoglycemia or hyperglycemia: Serum glucose control may be altered; carefully monitor patient and adjust insulin requirements accordingly. Renal impairment: Dosage reduction may be necessary.

Drug Side Effects ::

 Adverse Reactions

CNS: Headache; dizziness; lightheadedness; fatigue; sinus bradycardia; conduction abnormalities; arrhythmias. GI: Nausea; constipation; flatulence; diarrhea; abdominal pain or discomfort; loose stools; vomiting; fat malabsorption. HEPA: Increased liver transaminase. META: Hyperglycemia; hypoglycemia. OTHER: Injection site pain; flushing; asthenia; weakness.

Drug Mode of Action ::  

 Action Actions mimic those of natural hormone somatostatin. Suppresses secretion of serotonin and gastroenteropancreatic peptides (eg, gastrin, insulin, glucagon, secretin, motilin). Also suppresses growth hormone.

Drug Interactions ::

 Interactions

Cyclosporine: May decrease plasma levels of cyclosporine. INCOMPATIBILITIES: Parenteral nutrition solutions.

Drug Assesment ::

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies.
• Monitor glucose, CBC, T₃, T₄, TSH, renal function tests, BUN, creatinine, and electrolytes and obtain baseline weight and BP.
• Assess for nausea, headache, shortness of breath, hyperglycemia/hypoglycemia, or abdominal pain.
• Monitor I&O and daily weight.
• Monitor BP, pulse, and respiration weekly during treatment.
• Assess frequency and consistency of stools.
• Assess lung sounds, and report any edema or decrease in urine output.
• Dietary fat absorption may be altered in some patients. Perform periodic quantitative 72-hour fecal fat and serum carotene determination to aid in assessment of possible drug-induced aggravation of fat malabsorption.

Drug Storage/Management ::

 Administration/Storage

• Do not administer if particulate matter or discoloration is observed.
• Rotate sites for SC injection.
• Store ampules at room temperature for day of use.
• Refrigerate for prolonged storage.

Drug Notes ::

 Patient/Family Education

• Instruct and observe return demonstration of correct technique for SC injection. Explain that preferred sites for injection are abdomen, thigh, and hip.
• Advise patient of importance of regular follow-up with physician.
• Caution patient to report the following symptoms to physician: Icterus, jaundice, dark urine, or clay-colored stools.
• Advise patient to notify physician of abdominal pain, edema, chest pain, fainting, dry mouth, or shortness of breath.
• Advise patient that various laboratory tests may be required during therapy.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.